Anti-IL6R role in treatment of COVID-19-related ARDS

Anti-IL6R role in treatment of COVID-19-related ARDS

Bibliographic Details
Main Authors:	Franco Maria Buonaguro, Igor Puzanov, Paolo Antonio Ascierto
Format:	Article
Language:	English
Published:	BMC 2020-04-01
Series:	Journal of Translational Medicine
Subjects:	COVID-19 SARS-CoV-2 ARDS IL-6 Tocilizumab
Online Access:	http://link.springer.com/article/10.1186/s12967-020-02333-9

Similar Items

Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence
by: Corrado Pelaia, et al.
Published: (2021-03-01)

Why tocilizumab could be an effective treatment for severe COVID-19?
by: Binqing Fu, et al.
Published: (2020-04-01)

The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review
by: Avi Gurion Kaye, et al.
Published: (2020-11-01)

Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment
by: Jian Wu, et al.
Published: (2021-03-01)

How to follow-up a patient who received tocilizumab in severe COVID-19: a case report
by: Regina B. Podlasin, et al.
Published: (2020-08-01)

Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6
by: Robert Flisiak, et al.
Published: (2021-04-01)

Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation
by: Nicola Potere, et al.
Published: (2020-11-01)

Acute Cor Pulmonale in COVID-19-Related ARDS
by: Pierre Huette, MD, et al.
Published: (2020-07-01)

Tocilizumab as a Treatment for ‘Cytokine Storm Syndrome’ in COVID-19: A Case Report
by: Ari Fahrial Syam, et al.
Published: (2021-07-01)

Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation
by: Francesco Menzella, et al.
Published: (2020-09-01)

Temporal Clinical and Laboratory Response to Interleukin-6 Receptor Blockade With Tocilizumab in 89 Hospitalized Patients With COVID-19 Pneumonia
by: Daria Fomina, et al.
Published: (2020-10-01)

Incidence of secondary bacterial infections following utilization of tocilizumab for the treatment of COVID-19 – A matched retrospective cohort study
by: Joanna L Moore, et al.
Published: (2021-01-01)

Current Status of Cell-Based Therapies for COVID-19: Evidence From Mesenchymal Stromal Cells in Sepsis and ARDS
by: Zhiheng Xu, et al.
Published: (2021-10-01)

Administration Timing and Efficacy of Tocilizumab in Patients With COVID-19 and Elevated IL-6
by: Pan Li, et al.
Published: (2021-04-01)

Addition of Tocilizumab to the Standard of Care Reduces Mortality in Severe COVID-19: A Systematic Review and Meta-Analysis
by: Umesha Boregowda, et al.
Published: (2020-10-01)

Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size
by: Hong Zhao, et al.
Published: (2021-01-01)

Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation During Acute Respiratory Distress: A Case Report and Literature Review
by: Faryal Farooqi, et al.
Published: (2020-07-01)

Multimodality treatment in immunocompromised patients with severe COVID‐19: the role of IL‐6 inhibitor, intravenous immunoglobulin, and haemoperfusion
by: Nophol Leelayuwatanakul, et al.
Published: (2021-04-01)

A patient presenting with ARDS after COVID-19 vaccination: A COVID-19 case report
by: Ayse Sahin Tutak, et al.
Published: (2021-10-01)

Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study
by: Tariq Kewan, et al.
Published: (2020-07-01)

The Outcome of Six Patients with COVID-19 Infection and Multiple Myeloma. A Case Series and Literature Review
by: Hesham Elsabah, et al.
Published: (2020-10-01)

Stem cell therapy in COVID-19: Pooled evidence from SARS-CoV-2, SARS-CoV, MERS-CoV and ARDS: A systematic review
by: Saniya Mahendiratta, et al.
Published: (2021-05-01)

IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome
by: Etienne Dufranc, et al.
Published: (2020-04-01)

Efficacy of tocilizumab in patients with severe COVID-19: Survival and clinical outcomes
by: Abeer Al-Baadani, et al.
Published: (2021-08-01)

Host–Viral Interactions Revealed among Shared Transcriptomics Signatures of ARDS and Thrombosis: A Clue into COVID-19 Pathogenesis
by: Aastha Mishra, et al.
Published: (2020-10-01)

Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study
by: Jing Zhang, et al.
Published: (2020-10-01)

The Immune Response and Immunopathology of COVID-19
by: Esmaeil Mortaz, et al.
Published: (2020-08-01)

IL-6 Inhibition in Critically Ill COVID-19 Patients Is Associated With Increased Secondary Infections
by: Lucas M. Kimmig, et al.
Published: (2020-10-01)

Pathogenesis of IL-6 and potential therapeutic of IFN-γ in COVID-19
by: Ahmed Hasan Mohammed
Published: (2020-08-01)

Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?
by: Danfei Liu, et al.
Published: (2020-10-01)

Recombinant tissue plasminogen activator treatment for COVID-19 associated ARDS and acute cor pulmonale
by: Djuro Kosanovic, et al.
Published: (2021-03-01)

Lung Transplantation as a way to Escape Pneumonia in Patients with COVID-19: Lessons from ARDS and Influenza
by: Reyhaneh Shams Khozani, et al.
Published: (2021-07-01)

Interleukin-6 (IL-6) inhibitors as therapeutic agents for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis
by: Rizaldy Taslim Pinzon, et al.
Published: (2021-08-01)

Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review
by: A. Cortegiani, et al.
Published: (2021-01-01)

The effect of tocilizumab, anakinra and prednisolone on antibody response to SARS-CoV-2 in patients with COVID-19: A prospective cohort study with multivariate analysis of factors affecting the antibody response
by: Seniha Başaran, et al.
Published: (2021-04-01)

Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19
by: Flavio A. Cadegiani, et al.
Published: (2020-07-01)

Candidemia in COVID‐19 treated with corticosteroids and tocilizumab
by: Koichiro Yamamoto, et al.
Published: (2021-09-01)

Remdesivir in Severe COVID-19 and Non-Invasive Ventilation: A Real-Life Experience
by: Francesca Simioli, et al.
Published: (2021-08-01)

Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused
by: Sachin Chaudhary, et al.
Published: (2020-09-01)

Battling COVID-19: using old weapons for a new enemy
by: Rohit Kumar, et al.
Published: (2020-05-01)